BioSpace News Archive

Poolbeg Pharma announces an update on its lead asset, POLB 001, a small molecule immunomodulator which aims to address a significant unmet need in severe influenza.

Spexis AG announced that that the company will present at BioEquity Europe, taking place May 17 & 18, 2022.

Biophytis SA announces it will participate, represented by its CEO Stanislas Veillet and its Business Development Director Benoit Canolle, at the Biotechnology Innovation Organization International Convention to be held in San Diego from the 13th to the 16th of June 2022, alongside thousands of world leaders in biotechnology and the pharmaceutical industry.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced financial results and operational highlights for the quarter ended March 31, 2022.

Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people to take action when it comes to psoriatic arthritis.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 2022 Jefferies Global Healthcare Conference, June 8-10, 2022.

Palatin Technologies, Inc. announced that it has entered into a securities purchase agreement with institutional investors pursuant to which Palatin will issue and sell 8,100,000 shares of its Series B convertible redeemable preferred stock and 900,000 shares of its Series C convertible redeemable preferred stock to such investors.

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the expansion of its program to offer patients seeking treatment for addiction access to a telehealth provider through its “find a provider tool”, along with in-person care options.

Unlearn®, developer of the first machine-learning technology that creates digital twins of patients in clinical trials to enable smaller, faster studies, today announced that the European Medicines Agency (EMA) recently released a draft qualification opinion providing a regulatory framework for the application of the company’s TwinRCT™ solution to Phase 2 and 3 clinical trials.

Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases.